started · updated
IDEAYA Biosciences advances cancer drug trials and regulatory filings
IDEAYA Biosciences is progressing with clinical development and regulatory milestones for its oncology pipeline. The company has reached alignment with the FDA on registrational trial designs for IDE849, a DLL3-targeting antibody-drug conjugate. Plans are underway to initiate a single-arm extension cohort for gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) and a randomized phase 3 trial for various neuroendocrine carcinoma subtypes by the end of 2026. Additionally, a phase 3 trial for extensive-stage small cell lung cancer is expected to begin by year-end.
Separately, the company’s lead drug, darovasertib, is approaching regulatory review. IDEAYA completed a new drug application (NDA) in the third quarter for the use of darovasertib in combination with Pfizer’s crizotinib to treat metastatic uveal melanoma. The application was submitted under the FDA’s Real-Time Oncology Review program, with management expecting the FDA to accept the application for review within the current quarter. A potential commercial launch is targeted for the first half of 2027.
Entities
FDA · Ideaya Biosciences · Pfizer · Yujiro Hata · darovasertib · iQIYI